

Stuart J Connolly

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11657861/stuart-j-connolly-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

380
papers

53,871
citations

100
h-index

229
g-index

401
ext. papers

63,373
ext. citations

11.4
avg, IF

7.08
L-index

#	Paper	IF	Citations
380	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , 2022 ,	16.7	5
379	Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke.. <i>Europace</i> , 2022 ,	3.9	2
378	Dose-limiting, adverse event-associated bradycardia with ß-blocker treatment of atrial fibrillation in the GENETIC-AF trial.. <i>Heart Rhythm O2</i> , 2022 , 3, 40-49	1.5	
377	Prospective long-term follow-up of silicone-polyurethane-insulated implantable cardioverter-defibrillator leads.. <i>Heart Rhythm O2</i> , 2022 , 3, 57-64	1.5	1
376	Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleeding.. <i>Journal of the American College of Emergency Physicians Open</i> , 2022 , 3, e12655	1.6	0
375	Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. <i>Stroke</i> , 2021 , STROKEAHA121034572	6.7	2
374	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab513	1	0
373	Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e008548	7.6	4
372	Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation. <i>Circulation</i> , 2021 , 143, 1863-1873	16.7	6
371	Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 558-567	16.2	29
370	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021 , 107, 1130-1137	5.1	0
369	Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 803-809	3.8	1
368	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	1
367	Prevalence of Left Atrial Thrombus in Anticoagulated Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2875-2886	15.1	7
366	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021 , 52, 2096-2105	6.7	5
365	Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. <i>New England Journal of Medicine</i> , 2021 , 384, 2081-2091	59.2	77
364	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021 , 117, 942-949	9.9	7

363	Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals. <i>Cardiovascular Research</i> , 2021 , 117, 1523-1531	9.9	11
362	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 518-528	7	2
361	Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. <i>JAMA Neurology</i> , 2021 , 78, 11-20	17.2	5
360	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. <i>American Heart Journal</i>	4.9	2
359	Semi-automatic measurement of intracranial hemorrhage growth on non-contrast CT. <i>International Journal of Stroke</i> , 2021 , 16, 192-199	6.3	2
358	High-Sensitivity Estimate of the Incidence of New-Onset Atrial Fibrillation in Critically Ill Patients 2021 , 3, e0311		2
357	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 1097-1106	7	5
356	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 14-23	15.1	9
355	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
354	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e009591	6.4	1
353	Incidence and Predictors of Heart Failure in Patients With Atrial Fibrillation.. <i>CJC Open</i> , 2021 , 3, 1482-1489		1
352	LVS-HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry. <i>Journal of the American Heart Association</i> , 2021 , 10, e017735	6	1
351	Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. <i>Stroke</i> , 2021 , STROKEAHA120032976	6.7	0
350	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e018984	6	9
349	Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. <i>Circulation</i> , 2020 , 142, 1697-1699	16.7	5
348	The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. <i>American Heart Journal</i> , 2020 , 225, 69-77	4.9	16
347	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2287-2295	15.4	5
346	Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020 , 51, 2139-2147	6.7	2

345	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020 , 141, 1141-1151	16.7	21
344	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020 , 22, 870-877	3.9	9
343	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. <i>Circulation</i> , 2020 , 141, 1841-1854	16.7	53
342	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020 , 15, e0226259	3.7	0
341	Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020 , 51, 938-943	6.7	19
340	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020 , 29, 104936	2.8	8
339	Rate, Time Course, and Predictors of Implantable Cardioverter Defibrillator Infections: An Analysis From the SIMPLE Trial. <i>CJC Open</i> , 2020 , 2, 354-359	2	2
338	Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Neurology</i> , 2020 , 77, 1233-1240	17.2	11
337	Active-Fixation Atrial Leads and the Risk of Atrial Fibrillation: Insights From ASSERT. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e008655	6.4	0
336	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , 2020 , 51, 2901-2909	6.7	5
335	Permanent Bilateral Carotid Filters for Stroke Prevention in Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2020 , 22, 144	4.2	0
334	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. <i>JAMA Neurology</i> , 2020 , 77, 43-48	17.2	25
333	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 296-307	3.9	17
332	Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020 , 51, 1797-1804	6.7	18
331	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019 , 140, 1451-1459	16.7	22
330	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. <i>Stroke</i> , 2019 , 50, 3184-3190	6.7	39
329	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1519-1528	15.1	17
328	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019 , 139, 1134-1145	16.7	72

327	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019 , 140, 529-537	16.7	50
326	Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019 , 28, 2273-2279	2.8	15
325	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2243-2250	15.1	24
324	Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation. <i>Circulation</i> , 2019 , 139, 2846-2856	16.7	9
323	Prospective Study of Tricuspid Regurgitation Associated With Permanent Leads After Cardiac Rhythm Device Implantation. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 389-395	3.8	14
322	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. <i>Europace</i> , 2019 , 21, 1023-1030	3.9	4
321	Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. <i>JAMA Neurology</i> , 2019 , 76, 764-773	17.2	79
320	Effectiveness of single- vs dual-coil implantable defibrillator leads: An observational analysis from the SIMPLE study. <i>Journal of Cardiovascular Electrophysiology</i> , 2019 , 30, 1078-1085	2.7	0
319	Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 753-761	27.4	83
318	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , 2019 , 8, e010510	6	24
317	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019 , 380, 1326-1335	59.2	431
316	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019 , 14, 270-281	6.3	9
315	Defibrillation testing and clinical outcomes after implantable cardioverter-defibrillator implantation in patients in atrial fibrillation at the time of implant: An analysis from the SIMPLE trial. <i>Heart Rhythm</i> , 2019 , 16, 83-90	6.7	1
314	Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019 , 50, 2477-2485	6.7	47
313	Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. <i>European Heart Journal</i> , 2019 , 40, 3026-3032	9.5	9
312	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019 , 157, 682-691.e2	13.3	181
311	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3271-3280	15.1	56
310	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. <i>JACC: Heart Failure</i> , 2019 , 7, 586-598	7.9	13

309	Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019 , 157, 403-412.e5	13.3	62
308	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2845-2854	15.1	44
307	Atrial fibrillation detected initially during acute medical illness: A systematic review. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 130-141	4.3	22
306	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial. <i>Journal of the American Heart Association</i> , 2019 , 8, e010107	6	12
305	Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeons. <i>Europace</i> , 2019 , 21, 445-450	3.9	4
304	Effectiveness of implementation interventions in improving physician adherence to guideline recommendations in heart failure: a systematic review. <i>BMJ Open</i> , 2018 , 8, e017765	3	36
303	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <i>Canadian Journal of Cardiology</i> , 2018 , 34, 295-302	3.8	17
302	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. <i>European Heart Journal</i> , 2018 , 39, 477-485	9.5	63
301	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. <i>American Heart Journal</i> , 2018 , 198, 169-177	4.9	6
300	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e005795	6	19
299	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018 , 199, 51-58	4.9	7
298	Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trial. <i>American Heart Journal</i> , 2018 , 199, 75-82	4.9	17
297	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018 , 39, 750-757a	9.5	56
296	Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). <i>American Heart Journal</i> , 2018 , 201, 160-163	4.9	19
295	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2306-2315	15.1	173
294	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018 , 27, 1673-1682	2.8	37
293	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) study. <i>Europace</i> , 2018 , 20, 253-262	3.9	10
292	Atrial fibrillation occurring transiently with stress. <i>Current Opinion in Cardiology</i> , 2018 , 33, 58-65	2.1	18

291	Prevention of Stroke in Atrial Fibrillation 2018 , 1092-1100		
290	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018 , 39, 3973-3979	9.5	79
289	Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. <i>Open Heart</i> , 2018 , 5, e000800	3	8
288	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 255-267	15.1	36
287	Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2603-2611	15.1	58
286	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 2325-2334	40	142
285	Sedation strategies for defibrillation threshold testing: safety outcomes with anaesthesiologist compared to proceduralist-directed sedation: an analysis from the SIMPLE study. <i>Europace</i> , 2018 , 20, 1798-1803	3.9	
284	Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]). <i>American Journal of Cardiology</i> , 2018 , 121, 584-589	3	12
283	Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. <i>Heart Rhythm</i> , 2018 , 15, 386-392	6.7	9
282	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	40	204
281	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414
280	Prevention of Arrhythmia Device Infection Trial: The PADIT Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 3098-3109	15.1	83
279	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. <i>Lancet Neurology, The</i> , 2018 , 17, 1053-1060	24.1	99
278	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018 , 379, 987	59.2	20
277	Design and rationale of the atrial fibrillation occurring transiently with stress (AFOTS) follow-up cohort study. <i>Clinical Cardiology</i> , 2018 , 41, 1273-1280	3.3	12
276	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018 , 70, 828-835	1.6	10
275	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018 , 378, 2191-2201	59.2	432
274	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. <i>JAMA Cardiology</i> , 2017 , 2, 324-331	16.2	23

273	Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. <i>Heart Rhythm</i> , 2017 , 14, 801-807	6.7	71
272	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017 , 103, 1015-1023	5.1	58
271	Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. <i>Stroke</i> , 2017 , 48, 867-872	6.7	264
270	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017 , 189, 137-145	4.9	170
269	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 295-301	3.9	2
268	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017 , 190, 94-103	4.9	34
267	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017 , 33, 1027-1035	3.8	97
266	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017 , 38, 1339-1344	9.5	282
265	Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. <i>JAMA Cardiology</i> , 2017 , 2, 566-574	16.2	72
264	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017 , 19, 1630-1636	3.9	10
263	Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes in patients with preserved left ventricular function: a meta-analysis. <i>Europace</i> , 2017 , 19, 282-288	3.9	19
262	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
261	Subclinical Atrial Fibrillation in Older Patients. <i>Circulation</i> , 2017 , 136, 1276-1283	16.7	130
260	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017 , 1, e139-e145	2.7	15
259	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. <i>Europace</i> , 2017 , 19, 1002-1006	3.9	13
258	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016 , 134, 1697-1707	16.7	58
257	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016 , 375, 1131-41	59.2	580
256	Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke: Embolic Stroke of Undetermined Source Global Registry. <i>Stroke</i> , 2016 , 47, 2197-202	6.7	43

255	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016 , 139, 77-81	8.2	23
254	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016 , 18, 973-8	3.9	16
253	Troponin levels after ICD implantation with and without defibrillation testing and their predictive value for outcomes: Insights from the SIMPLE trial. <i>Heart Rhythm</i> , 2016 , 13, 504-10	6.7	12
252	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016 , 45, 77-83	3	72
251	D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 921-30	7	28
250	D-dimer and factor VIIa in atrial fibrillation [prognostic values for cardiovascular events and effects of anticoagulation therapy. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 921-930	7	29
249	Apical versus Non-Apical Lead: Is ICD Lead Position Important for Successful Defibrillation?. <i>Journal of Cardiovascular Electrophysiology</i> , 2016 , 27, 581-6	2.7	7
248	Effectiveness of implementation strategies in improving physician adherence to guideline recommendations in heart failure: a systematic review protocol. <i>BMJ Open</i> , 2016 , 6, e009364	3	11
247	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016 , 1, 146-154	5.6	65
246	High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. <i>Open Heart</i> , 2016 , 3, e000515	3	32
245	Andexanet Alfa for Factor Xa Inhibitor Reversal. <i>New England Journal of Medicine</i> , 2016 , 375, 2499-500	59.2	19
244	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016 , 387, 2302-2311	40	272
243	Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. <i>International Journal of Stroke</i> , 2016 , 11, 526-33	6.3	86
242	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). <i>Circulation</i> , 2016 , 134, 589-98	16.7	116
241	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , 2016 , 388, 1161-9	40	157
240	Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. <i>European Heart Journal</i> , 2015 , 36, 281-7a	9.5	196
239	Response to letter regarding article "Temporal relationship between subclinical atrial fibrillation and embolic events". <i>Circulation</i> , 2015 , 131, e337-8	16.7	
238	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes. <i>Circulation</i> , 2015 , 132, 796-803	16.7	62

237	Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. <i>International Journal of Cardiology</i> , 2015 , 196, 127-31	3.2	58
236	Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). <i>Lancet, The</i> , 2015 , 385, 785-91	4.0	161
235	Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. <i>Stroke</i> , 2015 , 46, 667-72	6.7	36
234	Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. <i>New England Journal of Medicine</i> , 2015 , 373, 1295-306	59.2	605
233	Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2015 , 116, 1204-9 ³		42
232	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015 , 170, 1151-60	4.9	73
231	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. <i>New England Journal of Medicine</i> , 2015 , 373, 2413-24	59.2	754
230	Reply: Anticoagulant-Related Nephropathy. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2682 ^{5.1}	0	
229	Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score. <i>Circulation Journal</i> , 2015 , 79, 2138-47	2.9	11
228	Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. <i>Thrombosis and Haemostasis</i> , 2015 , 113, 625-32	7	158
227	Letter by Longtin et al regarding article, "Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry". <i>Circulation</i> , 2015 , 131, e517	16.7	
226	Global survey of the diagnostic evaluation and management of cryptogenic ischemic stroke. <i>International Journal of Stroke</i> , 2015 , 10, 1031-6	6.3	34
225	Efficacy of Hospital at Home in Patients with Heart Failure: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0129282	3.7	41
224	Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2481-93	15.1	130
223	Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. <i>Cardiology Research</i> , 2015 , 6, 267-277	1.8	0
222	Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. <i>Circulation</i> , 2014 , 129, 961-70	16.7	293
221	Temporal relationship between subclinical atrial fibrillation and embolic events. <i>Circulation</i> , 2014 , 129, 2094-9	16.7	402
220	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 2242-8a	9.5	34

219	Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. <i>Circulation</i> , 2014 , 129, 1568-76	16.7	250
218	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. <i>Heart</i> , 2014 , 100, 1193-200	5.1	39
217	Embolic strokes of undetermined source: the case for a new clinical construct. <i>Lancet Neurology</i> , 2014 , 13, 429-38	24.1	923
216	ACP Journal Club. Review: New oral anticoagulants increase GI bleeding in venous thrombosis and ACS. <i>Annals of Internal Medicine</i> , 2014 , 160, JC4	8	
215	Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial. <i>Stroke</i> , 2014 , 45, 2989-94	6.7	11
214	Interaction between digoxin and dronedarone in the PALLAS trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014 , 7, 1019-25	6.4	57
213	Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". <i>Circulation</i> , 2014 , 130, e195	16.7	1
212	Prevention of Stroke in Patients With Atrial Fibrillation 2014 , 1129-1137		
211	Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. <i>Europace</i> , 2014 , 16, 174-81	3.9	28
210	An individual patient-based meta-analysis of the effects of dronedarone in patients with atrial fibrillation. <i>Europace</i> , 2014 , 16, 1117-24	3.9	7
209	Additional events in the RE-LY trial. <i>New England Journal of Medicine</i> , 2014 , 371, 1464-5	59.2	43
208	Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". <i>Circulation</i> , 2014 , 130, e95	16.7	
207	Prospective long-term evaluation of Optim-insulated (Riata ST Optim and Durata) implantable cardioverter-defibrillator leads. <i>Heart Rhythm</i> , 2014 , 11, 2156-62	6.7	20
206	Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 692-700	27.4	391
205	Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 933-42	7	82
204	Predictors of early and late stroke following cardiac surgery. <i>Cmaj</i> , 2014 , 186, 905-11	3.5	38
203	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014 , 35, 1856-63	9.5	20
202	The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 881-8	15.1	585

201	Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , 2014 , 113, 669-75	3	13
200	Reply: regarding the effect of dabigatran plasma concentrations. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2885-6	15.1	3
199	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 435-42	5.1	9
198	Atrial fibrillation in heart failure: stroke risk stratification and anticoagulation. <i>Heart Failure Reviews</i> , 2014 , 19, 305-13	5	17
197	Tricuspid valve regurgitation following temporary or permanent endocardial lead insertion, and the impact of cardiac resynchronization therapy. <i>Open Cardiovascular Medicine Journal</i> , 2014 , 8, 113-20	0.7	13
196	Dabigatran versus warfarin in patients with mechanical heart valves. <i>New England Journal of Medicine</i> , 2013 , 369, 1206-14	59.2	919
195	Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. <i>Stroke</i> , 2013 , 44, 1891-6	6.7	219
194	Management and outcomes of major bleeding during treatment with dabigatran or warfarin. <i>Circulation</i> , 2013 , 128, 2325-32	16.7	222
193	Left Atrial Appendage Occlusion Study II (LAAOS II). <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1443-7	3.8	73
192	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013 , 128, 237-43	16.7	166
191	Ethnic differences in atrial fibrillation identified using implanted cardiac devices. <i>Journal of Cardiovascular Electrophysiology</i> , 2013 , 24, 381-7	2.7	43
190	Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>Circulation</i> , 2013 , 127, 634-40	16.7	387
189	Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 295-301	5.1	53
188	Randomized cluster crossover trials for reliable, efficient, comparative effectiveness testing: design of the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Canadian Journal of Cardiology</i> , 2013 , 29, 652-8	3.8	44
187	Reply to the Editor--Shocks and mortality versus pacing and mortality. <i>Heart Rhythm</i> , 2013 , 10, e9-10	6.7	
186	Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 246-52.e1-5	6.9	56
185	Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 224-8	3.8	64
184	Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 900-8	15.1	48

183	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013 , 34, 170-6	9.5	134
182	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , 2013 , 34, 2752-9	9.5	20
181	Response to letters regarding article, Peri-procedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial. <i>Circulation</i> , 2013 , 127, e506	16.7	2
180	Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy". <i>Circulation</i> , 2013 , 127, e278-9	16.7	1
179	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <i>European Heart Journal</i> , 2013 , 34, 1498-505	9.5	97
178	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. <i>European Journal of Heart Failure</i> , 2013 , 15, 1053-61	12.3	65
177	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology</i> , 2012 , 11, 225-31	24.1	132
176	A randomized-controlled pilot study comparing ICD implantation with and without intraoperative defibrillation testing in patients with heart failure and severe left ventricular dysfunction: a substudy of the RAFT trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2012 , 23, 1313-6	2.7	30
175	Venice Chart international consensus document on atrial fibrillation ablation: 2011 update. <i>Journal of Cardiovascular Electrophysiology</i> , 2012 , 23, 890-923	2.7	65
174	Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012 , 21, 429-35	2.8	79
173	Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. <i>Heart Rhythm</i> , 2012 , 9, 1241-6	6.7	108
172	Reply to the Editor. Electrogram Confirmation of Atrial High-Rate Episodes. <i>Heart Rhythm</i> , 2012 , 9, e17-e18	6.7	
171	Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. <i>Heart Rhythm</i> , 2012 , 9, 2068-74	6.7	21
170	Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. <i>Stroke</i> , 2012 , 43, 1511-7	6.7	333
169	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012 , 129, 715-9	8.2	32
168	Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. <i>Blood</i> , 2012 , 119, 2172-4	2.2	191
167	Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. <i>Stroke</i> , 2012 , 43, 3291-7	6.7	70
166	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). <i>American Heart Journal</i> , 2012 , 163, 931-937.e1	4.9	139

165	The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 95-101	3.8	5
164	Age and mental health predict early device-specific quality of life in patients receiving prophylactic implantable defibrillators. <i>Canadian Journal of Cardiology</i> , 2012 , 28, 502-7	3.8	8
163	Atrial overdrive pacing to prevent atrial fibrillation: insights from ASSERT. <i>Heart Rhythm</i> , 2012 , 9, 1667-73	7.7	38
162	Subclinical atrial fibrillation and the risk of stroke. <i>New England Journal of Medicine</i> , 2012 , 366, 120-9	59.2	1337
161	The rationale and design of the Shockless IMPLant Evaluation (SIMPLE) trial: a randomized, controlled trial of defibrillation testing at the time of defibrillator implantation. <i>American Heart Journal</i> , 2012 , 164, 146-52	4.9	25
160	Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. <i>Heart Rhythm</i> , 2012 , 9, 217-224.e2	6.7	6
159	Randomised comparison of a simple warfarin dosing algorithm versus a computerised anticoagulation management system for control of warfarin maintenance therapy. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 1228-35	7	20
158	Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. <i>Circulation</i> , 2012 , 126, 343-8	16.7	409
157	Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012 , 35, 131-4	1.6	75
156	Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 2012 , 23, 462-72	2.7	10
155	Cardiac resynchronization therapy in patients with permanent atrial fibrillation: results from the Resynchronization for Ambulatory Heart Failure Trial (RAFT). <i>Circulation: Heart Failure</i> , 2012 , 5, 566-70	7.6	110
154	Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. <i>Circulation</i> , 2012 , 126, 2300-7	16.7	108
153	Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. <i>Circulation</i> , 2012 , 125, 669-76	16.7	306
152	Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012 , 5, 273-4		21
151	Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. <i>Circulation</i> , 2012 , 125, 1605-16	16.7	291
150	Reply to Letters Regarding Article, Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. <i>Circulation</i> , 2012 , 125,	16.7	2
149	Relevance of electrical remodeling in human atrial fibrillation: results of the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial mechanisms of atrial fibrillation study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012 , 5, 626-31	6.4	19
148	Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians". <i>Stroke</i> , 2012 , 43, e46-7; author reply e49	6.7	

147	Antiarrhythmic Drug Therapy for New-Onset Ventricular Arrhythmia (VT/VF) in ICD Patients. <i>Cardiac Electrophysiology Clinics</i> , 2011 , 3, 651-661	1.4	1
146	Apixaban in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 364, 806-17	59.2	1772
145	Dronedarone in high-risk permanent atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 2268-76	59.2	438
144	Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial. <i>Circulation Journal</i> , 2011 , 75, 800-5	2.9	87
143	Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. <i>Annals of Internal Medicine</i> , 2011 , 155, 660-7, W204	8	157
142	Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. <i>Annals of Internal Medicine</i> , 2011 , 155, 579-86	8	97
141	Effects of dronedarone on clinical outcomes in patients with lone atrial fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. <i>Journal of Cardiovascular Electrophysiology</i> , 2011 , 22, 770-6	2.7	13
140	Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). <i>American Journal of Cardiology</i> , 2011 , 107, 1019-22	3	47
139	Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. <i>Circulation</i> , 2011 , 123, 131-6	16.7	380
138	Irbesartan in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 364, 928-38	59.2	193
137	Computerized clinical decision support systems for therapeutic drug monitoring and dosing: a decision-maker-researcher partnership systematic review. <i>Implementation Science</i> , 2011 , 6, 90	8.4	64
136	Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. <i>Circulation</i> , 2011 , 124, 2649-60	16.7	35
135	Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. <i>Europace</i> , 2011 , 13, 1118-26	3.9	26
134	Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. <i>Circulation</i> , 2011 , 123, 2363-72	16.7	872
133	Atrial fibrillation in 2010: advances in treatment and management. <i>Nature Reviews Cardiology</i> , 2011 , 8, 67-8	14.8	7
132	Canadian Registry of ICD Implant Testing procedures (CREDIT): current practice, risks, and costs of intraoperative defibrillation testing. <i>Journal of Cardiovascular Electrophysiology</i> , 2010 , 21, 177-82	2.7	32
131	Explaining the RE-LY Trial. <i>Canadian Journal of Hospital Pharmacy</i> , 2010 , 63, 334-6	0.5	
130	Mechanisms underlying the lack of effect of implantable cardioverter-defibrillator therapy on mortality in high-risk patients with recent myocardial infarction: insights from the Defibrillation in Acute Myocardial Infarction Trial (DINAMIT). <i>Circulation</i> , 2010 , 122, 2645-52	16.7	92

129	Dabigatran and warfarin in vitamin K antagonist-naïve and -experienced cohorts with atrial fibrillation. <i>Circulation</i> , 2010 , 122, 2246-53	16.7	138
128	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010 , 31, 2133-40	9.5	26
127	Cognitive function and anticoagulation control in patients with atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010 , 3, 277-83	5.8	79
126	Dronedaron in patients with congestive heart failure: insights from ATHENA. <i>European Heart Journal</i> , 2010 , 31, 1717-21	9.5	48
125	A rare cause of implantable cardioverter-defibrillator failure: short-circuiting via an unused pace/sense lead. <i>Heart Rhythm</i> , 2010 , 7, 1630-1	6.7	3
124	Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). <i>Heart Rhythm</i> , 2010 , 7, 1171-7	6.7	31
123	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. <i>New England Journal of Medicine</i> , 2010 , 363, 1704-14	59.2	428
122	Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1796-802	15.1	108
121	Dronedaron for atrial fibrillation have we expanded the antiarrhythmic armamentarium?. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1353-4; author reply 1354-5	15.1	
120	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. <i>Thrombosis Research</i> , 2010 , 125, e128-31	8.2	9
119	Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. <i>American Heart Journal</i> , 2010 , 159, 348-353.e1	4.9	118
118	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet, The</i> , 2010 , 376, 975-83	40	754
117	Newly identified events in the RE-LY trial. <i>New England Journal of Medicine</i> , 2010 , 363, 1875-6	59.2	584
116	Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 633-41	7	263
115	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology, The</i> , 2010 , 9, 1157-1163	24.1	329
114	Effect of dronedaron on cardiovascular events in atrial fibrillation. <i>New England Journal of Medicine</i> , 2009 , 360, 668-78	59.2	764
113	Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedaron 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. <i>Circulation</i> , 2009 , 120, 1174-80	16.7	169
112	Left atrial appendage occlusion does not eliminate the need for warfarin. <i>Circulation</i> , 2009 , 120, 1927-32; discussion 1932	16.7	49

111	Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. <i>Circulation</i> , 2009 , 119, 606-18	16.7	378
110	Effect of clopidogrel added to aspirin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2009 , 360, 2066-78	59.2	874
109	Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hematoma following surgery for pacemakers and implantable defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009 , 32, 378-82	1.6	77
108	A systematic review of randomized trials comparing radiofrequency ablation with antiarrhythmic medications in patients with atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2009 , 20, 138-44	2.7	91
107	Design and use of a quantitative scale for measuring presyncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2009 , 20, 888-93	2.7	10
106	Dabigatran versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2009 , 361, 1139-51	59.2	7909
105	Potential demographic and baseline variables for risk stratification of high-risk post-myocardial infarction patients in the era of implantable cardioverter-defibrillator—a prognostic indicator. <i>International Journal of Cardiology</i> , 2008 , 126, 101-7	3.2	9
104	Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. <i>American Heart Journal</i> , 2008 , 155, 829-40	4.9	14
103	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). <i>American Heart Journal</i> , 2008 , 156, 37-43	4.9	153
102	Rhythm control versus rate control for atrial fibrillation and heart failure. <i>New England Journal of Medicine</i> , 2008 , 358, 2667-77	59.2	1090
101	Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. <i>Circulation</i> , 2008 , 118, 2029-37	16.7	670
100	Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). <i>Stroke</i> , 2008 , 39, 1482-6	6.7	130
99	Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients with Atrial fibrillation/atrial flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 2008 , 19, 69-73	2.7	30
98	Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation. <i>Blood</i> , 2008 , 112, 33-33	2.2	11
97	Current Role of Medical Therapy for Prevention or Termination of Atrial Fibrillation 2008 , 185-195		1
96	The effect of atrial-based pacing on exercise capacity as measured by the 6-minute walk test: a substudy of the Canadian Trial of Physiological Pacing (CTOPP). <i>Heart Rhythm</i> , 2007 , 4, 1024-8	6.7	5
95	Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2156-61	15.1	354
94	Worsening of symptoms before presentation with vasovagal syncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2007 , 18, 954-9	2.7	11

93	Dronedaron for maintenance of sinus rhythm in atrial fibrillation or flutter. <i>New England Journal of Medicine</i> , 2007 , 357, 987-99	59.2	480
92	Challenges of establishing new antithrombotic therapies in atrial fibrillation. <i>Circulation</i> , 2007 , 116, 449-55.7	74	
91	Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. <i>European Heart Journal</i> , 2007 , 28, 1746-9	9.5	120
90	Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. <i>Journal of Hypertension</i> , 2007 , 25, 307-13	1.9	14
89	Clinical Trials of Pacing Modes 2007 , 337-356		
88	Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. <i>American Journal of Cardiology</i> , 2006 , 98, 215-8	3	31
87	Use and misuse of surrogate outcomes in arrhythmia trials. <i>Circulation</i> , 2006 , 113, 764-6	16.7	27
86	Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. <i>Circulation</i> , 2006 , 114, 104-9	16.7	135
85	Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. <i>Circulation</i> , 2006 , 114, 11-7	16.7	182
84	Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 165-71	27.4	515
83	Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. <i>Canadian Journal of Cardiology</i> , 2006 , 22, 485-8	3.8	7
82	Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. <i>American Heart Journal</i> , 2006 , 152, 967-73	4.9	138
81	Benefits of left atrial appendage occlusion. <i>American Heart Journal</i> , 2006 , 151, e3	4.9	1
80	ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). <i>American Heart Journal</i> , 2006 , 152, 442-7	4.9	94
79	Age of first faint in patients with vasovagal syncope. <i>Journal of Cardiovascular Electrophysiology</i> , 2006 , 17, 49-54	2.7	96
78	Omega-3 fatty acids and sudden arrhythmic death. <i>Herz</i> , 2006 , 31 Suppl 3, 59-64	2.6	
77	Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. <i>European Heart Journal</i> , 2005 , 26, 1385-93	9.5	62
76	Indication for antithrombotic therapy for atrial fibrillation: reconciling the guidelines with clinical practice. <i>Country Review Ukraine</i> , 2005 , 7, C28-C33		5

75	Cost-effectiveness of physiologic pacing: results of the Canadian Health Economic Assessment of Physiologic Pacing. <i>Heart Rhythm</i> , 2005 , 2, 270-5	6.7	14
74	Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. <i>American Heart Journal</i> , 2005 , 149, 489-96	4.9	264
73	Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. <i>American Heart Journal</i> , 2005 , 150, 288-93	4.9	354
72	Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1832-9	15.1	625
71	Prognostic impact of demographic factors and clinical features on the mode of death in high-risk patients after myocardial infarction—a combined analysis from multicenter trials. <i>Clinical Cardiology</i> , 2005 , 28, 471-8	3.3	10
70	Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. <i>Current Opinion in Cardiology</i> , 2005 , 20, 31-7	2.1	40
69	Canadian Trial of Physiological Pacing: Effects of physiological pacing during long-term follow-up. <i>Circulation</i> , 2004 , 109, 357-62	16.7	145
68	Role of oral anticoagulation in management of atrial fibrillation. <i>British Heart Journal</i> , 2004 , 90, 813-7		25
67	Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. <i>New England Journal of Medicine</i> , 2004 , 351, 2481-8	59.2	1063
66	The management of patients with carotid sinus syndrome: is pacing the answer?. <i>Clinical Autonomic Research</i> , 2004 , 14 Suppl 1, 80-6	4.3	30
65	Atrial fibrillation: guiding lessons from epidemiology. <i>Cardiology Clinics</i> , 2004 , 22, 1-8	2.5	6
64	Diminishing proportional risk of sudden death with advancing age: implications for prevention of sudden death. <i>American Heart Journal</i> , 2004 , 147, 837-40	4.9	79
63	The association of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation. <i>American Heart Journal</i> , 2004 , 148, 649-54	4.9	84
62	Asymptomatic or "silent" atrial fibrillation: frequency in untreated patients and patients receiving azimilide. <i>Circulation</i> , 2003 , 107, 1141-5	16.7	139
61	Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 2224-9	27.4	330
60	Atrial fibrillation after cardiac surgery: update on the evidence on the available prophylactic interventions. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 189-92		15
59	The Defibrillator in Acute Myocardial Infarction Trial (DINAMIT): rationale, design and specific aims. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003 , 7, 447-51		4
58	Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. <i>American Journal of Cardiology</i> , 2003 , 91, 9G-14G	3	159

57	Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, S60-3	2.7	27
56	Prevention of vascular events in patients with atrial fibrillation: evidence, guidelines, and practice. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, S52-5	2.7	6
55	Long-term amiodarone therapy and the risk of complications after cardiac surgery: results from the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT). <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2003 , 125, 633-7	1.5	14
54	Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. <i>American Heart Journal</i> , 2003 , 146, 489-93	4.9	22
53	Double-blind, placebo-controlled, randomized trial of prophylactic metoprolol for reduction of hospital length of stay after heart surgery: the beta-Blocker Length Of Stay (BLOS) study. <i>American Heart Journal</i> , 2003 , 145, 226-32	4.9	134
52	Effect of pacing mode on health-related quality of life in the Canadian Trial of Physiologic Pacing. <i>American Heart Journal</i> , 2003 , 145, 430-7	4.9	69
51	Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. <i>American Heart Journal</i> , 2003 , 145, 174-8	4.9	66
50	Preventing stroke in patients with atrial fibrillation: current treatments and new concepts. <i>American Heart Journal</i> , 2003 , 145, 418-23	4.9	24
49	Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial Fibrillation. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 388-394	2.9	6
48	Historical criteria that distinguish syncope from seizures. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 142-8	15.1	276
47	Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response. <i>American Heart Journal</i> , 2002 , 143, 643-9	4.9	35
46	Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. <i>American Heart Journal</i> , 2002 , 143, 984-90	4.9	184
45	Quality of life in the Canadian Implantable Defibrillator Study (CIDS). <i>American Heart Journal</i> , 2002 , 144, 282-9	4.9	223
44	Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. <i>Circulation</i> , 2002 , 106, 75-80	16.7	371
43	Quality of life in the Canadian Implantable Defibrillator Study (CIDS). <i>American Heart Journal</i> , 2002 , 144, 282-289	4.9	258
42	Circadian variation of paroxysmal atrial fibrillation. PA3 Investigators. Atrial Pacing Peri-ablation for Prevention of Atrial Fibrillation Trial. <i>American Journal of Cardiology</i> , 2001 , 87, 794-8, A8	3	20
41	Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. <i>American Journal of Cardiology</i> , 2001 , 88, 974-9	3	72
40	Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. <i>Circulation</i> , 2001 , 103, 3081-5	16.7	83

39	New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. <i>Circulation</i> , 2001 , 103, 2365-70	16.7	288
38	Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: the Canadian implantable defibrillator study. <i>Circulation</i> , 2001 , 104, 1622-6	16.7	50
37	Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). <i>Circulation</i> , 2001 , 103, 1416-21	16.7	96
36	Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 167-72	15.1	170
35	Trials of Physiologic Pacing. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000 , 4, 156-158		
34	Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. <i>Circulation</i> , 2000 , 101, 1297-302	16.7	1189
33	Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. <i>New England Journal of Medicine</i> , 2000 , 342, 1385-91	59.2	577
32	Randomized crossover comparison of DDDR versus VDD pacing after atrioventricular junction ablation for prevention of atrial fibrillation. The atrial pacing peri-ablation for paroxysmal atrial fibrillation (PA (3)) study investigators. <i>Circulation</i> , 2000 , 102, 736-41	16.7	97
31	Appropriate outcome measures in trials evaluating treatment of atrial fibrillation. <i>American Heart Journal</i> , 2000 , 139, 752-60	4.9	12
30	The defibrillator in acute myocardial infarction trial (DINAMIT): study protocol. <i>American Heart Journal</i> , 2000 , 140, 735-9	4.9	52
29	Clinical trials of pacing mode selection. <i>Cardiology Clinics</i> , 2000 , 18, 1-23, vii	2.5	18
28	Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 794-802	15.1	90
27	Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. <i>Circulation</i> , 1999 , 99, 2268-75	16.7	194
26	Evidence-based analysis of amiodarone efficacy and safety. <i>Circulation</i> , 1999 , 100, 2025-34	16.7	240
25	Atrial pacing periaablation for prevention of paroxysmal atrial fibrillation. <i>Circulation</i> , 1999 , 99, 2553-8	16.7	145
24	Meta-analysis of antiarrhythmic drug trials. <i>American Journal of Cardiology</i> , 1999 , 84, 90R-93R	3	38
23	Evolving Indications for Permanent Pacing in Patients with Vasovagal Syncope. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1998 , 2, 52-53		
22	The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. <i>American Journal of Cardiology</i> , 1998 , 82, 82N-85N	3	60

21	The Problem of Asymptomatic Ventricular Arrhythmias Among Survivors of Acute Myocardial Infarction: Role of Amiodarone. <i>ACC Current Journal Review</i> , 1998 , 7, 12-14		
20	Implantable cardioverter defibrillators--for whom?. <i>Lancet, The</i> , 1998 , 352, 338-40	40	7
19	Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. <i>Lancet, The</i> , 1997 , 349, 675-82	40	750
18	North American Vasovagal Pacemaker Study: study design and organization. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1997 , 20, 844-8	1.6	13
17	Dual-chamber versus ventricular pacing. Critical appraisal of current data. <i>Circulation</i> , 1996 , 94, 578-83	16.7	73
16	The problem of asymptomatic ventricular arrhythmias among survivors of acute myocardial infarction: Role of amiodarone. <i>ACC Current Journal Review</i> , 1995 , 4, 32-34		3
15	"An AVID dissent": commentary. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 1712-3	1.6	8
14	Standardized reporting of ICD patient outcome: the report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9-10, 1993. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993 , 16, 1358-62	1.6	66
13	Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT): rationale and protocol. CAMIAT Investigators. <i>American Journal of Cardiology</i> , 1993 , 72, 87F-94F	3	24
12	Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators. <i>American Journal of Cardiology</i> , 1993 , 72, 103F-108F	3	114
11	Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: the need for randomized trials. <i>American Journal of Cardiology</i> , 1992 , 69, 959-62	3	64
10	Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. <i>Journal of the American College of Cardiology</i> , 1991 , 18, 349-55	15.1	964
9	Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. <i>American Journal of Cardiology</i> , 1989 , 63, 817-9	3	68
8	Concentration response relationships of amiodarone and desethylamiodarone. <i>American Heart Journal</i> , 1988 , 115, 1208-13	4.9	17
7	Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery. <i>Journal of the American College of Cardiology</i> , 1987 , 10, 1145-8	15.1	58
6	Diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. <i>Acta Pharmacologica Et Toxicologica</i> , 1985 , 57 Suppl 2, 55-60		7
5	Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. <i>American Journal of Cardiology</i> , 1983 , 52, 490-4	3	699
4	Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. <i>American Journal of Cardiology</i> , 1983 , 52, 1208-13	3	84

- 3 Clinical pharmacokinetics of N-acetylprocainamide. *Clinical Pharmacokinetics*, **1982**, 7, 206-20 6.2 33
- 2 Periprocedural and Long-Term Anticoagulation77-84
- 1 Indications to Ventricular Tachycardia/Ventricular Fibrillation Ablation and Hybrid Therapy237-257